Short answer
Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Roche collaboration grants exclusive worldwide bexobrutideg rights, materially validating Nurix’s lead BTK degrader.
Nurix Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Roche collaboration grants exclusive worldwide bexobrutideg rights, materially validating Nurix’s lead BTK degrader
- $700M upfront payment plus up to $2.3B total potential payments, including upfront
- Nurix funds 40% of global development costs and shares U.S. profits and losses equally with Roche
- Roche leads ex-U.S. development and commercialization; Nurix receives low-teens to high-teens ex-U.S. royalties
- Agreement remains subject to HSR and other antitrust clearances, creating closing risk
Item 7.01 · Regulation FD Disclosure
- Nurix announced a collaboration agreement with Roche, making the partnership the key market-relevant disclosure
- Conference call and webcast scheduled for June 8, 2026, at 8:00 a.m. Eastern Time
- Press release and investor presentation filed as Exhibits 99.1 and 99.2 for collaboration details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nurix Therapeutics, Inc. 8-K filings
Get the next NRIX 8-K as it lands
Follow NRIX for push alerts, or ask the research agent what this filing means.